What are the precautions for taking brigatinib/brigatinib?

Brigatinib is a cancer drug used to treat non-small cell lung cancer in adults. It is used in patients who have never been treated with an ALK inhibitor or who have been previously treated with the ALK inhibitor crizotinib. Brigatinib is used only if the non-small cell lung cancer is ALK positive, which means something has changed in the cancer cells that affects the gene that makes a protein called ALK (anaplastic lymphoma kinase).

What are the precautions for taking Brigatinib/Brigatinib(Brigatinib)?

1.Interstitial lung disease (ILD)/Pneumonia:Monitor for new or worsening respiratory symptoms, particularly during the first week of treatment. If new or worsening respiratory symptoms occur, discontinue brigatinib and promptly evaluate for ILD/pneumonitis. After recovery, either reduce the dose or permanently discontinue brigatinib.

2.Hypertension: Monitor blood pressure after 2 weeks and at least once a month during treatment. For severe hypertension, discontinue brigatinib and then reduce the dose or permanently discontinue the drug.

3.Bradycardia:Monitor heart rate and blood pressure regularly during treatment. If symptoms occur, discontinue brigatinib and then reduce dose or permanently discontinue brigatinib.

4.Visual Impairment:Patients are advised to report visual symptoms. Discontinue brigatinib and obtain ophthalmologic evaluation, then reduce dose or permanently discontinue brigatinib.

5.Elevated creatine phosphokinase:Monitor CPK levels regularly during treatment. Discontinue brigatinib and resume or reduce dose based on severity and muscle pain or weakness.

6.Elevated pancreatic enzymes:Monitor lipase and amylase levels regularly during treatment. Depending on severity, withhold brigatinib and then resume or reduce dose.

7.Hepatotoxicity:Monitor alanine aminotransferase (ALT), aspartate aminotransferase (AST) and total bilirubin levels regularly during treatment. Depending on severity, withhold dosage and then resume at lower levels.

8.Hyperglycemia:Assess fasting blood glucose before starting brigatinib and periodically during treatment. If adequate control is not achieved with optimal medical management, brigatinib should be withheld and dose reduction or permanent discontinuation should be considered based on severity.

9.Photosensitivity:Patients are advised to limit sun exposure. Based on severity, discontinue brigatinib and resume at the same dose, reduce the dose, or permanently discontinue.

10.Embryo-Fetal Toxicity:can cause fetal harm, inform women of potential risks to the fetus with reproductive potential, and use effective contraceptive measures. Generic drugs of this drug are produced in Laos and Bangladesh, and they are all officially marketed generic drugs. The retail price of Laos United Pharmaceuticals90mg30tablets900RMB, the retail price of pharmaceuticals in Laos and ASEAN90mg21tablets190 The retail price of Beacon Pharmaceutical in Bangladesh is around 090mg30tablets3200yuan, and the retail price of Yaopin International Pharmaceutical in Bangladesh is around 90mg30pills2200yuan. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.

xa0

xa0